H. Lundbeck A/S (Lundbeck) and Ovation Pharmaceuticals, Inc. (Ovation) today announced that they have entered into a definitive transaction agreement under which Lundbeck, through the wholly owned subsidiary Lundbeck, Inc., will acquire Ovation in an all cash transaction valuing Ovation at up to USD 900 million or approximately DKK 5.2 billion.

Pfizer Inc and The Pfizer Foundation announced, on "World Cancer Day", that they have awarded $7 million in 2009 to help 13 non-governmental organizations (NGOs) focus on improving both treatment and prevention for cancer patients, through its Global Health Partnerships grants program (GHP). Since 2007, 29 Global Health Partnerships grants have been awarded to NGOs working in more than 46 countries around the world.

Amgen (Nasdaq: AMGN) announced that the European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim) for the treatment of splenectomised adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Sanofi-aventis announced that the European Commission has granted competition law clearance to the proposed acquisition of Zentiva NV (Zentiva) by sanofi-aventis Europe. Sanofi-aventis welcomes this decision, which will allow the Offer to proceed. The offer expiration date is maintained at February 20, 2009.

In 2008, Roche continued its strong sales performance. Total sales grew by 6% in local currencies (-1% in Swiss francs; 10% in US dollars) to 45.6 billion Swiss francs, with the Pharmaceuticals Division representing 79% of Group sales and the Diagnostics Division contributing 21%. The sales increase in the underlying business more than compensated for the anticipated decline in Tamiflu pandemic sales of 1.6 billion Swiss francs.

Roche today announced interim results from a phase III study (ATLAS) in patients with advanced non small cell lung cancer (NSCLC). The study was stopped early because of the significance of the interim data. The results showed that Tarceva (erlotinib) plus Avastin (bevacizumab) given as first line maintenance treatment following initial therapy with Avastin plus chemotherapy extends the time patients live without their disease getting worse (progression free survival) compared to maintenance therapy with Avastin plus placebo.

Patients treated with Lipitor® (atorvastatin calcium) 80 mg had a significant 55 percent reduction in levels of high-sensitivity C-reactive protein (hsCRP), while those taking Lipitor 10 mg had a significant 21 percent reduction in hsCRP levels at the end of 26 weeks compared to baseline, according to the results from the primary endpoint of a new study.